These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. Palomer X, Salvadó L, Barroso E, Vázquez-Carrera M. Int J Cardiol; 2013 Oct 09; 168(4):3160-72. PubMed ID: 23932046 [Abstract] [Full Text] [Related]
4. Western diet impairs metabolic remodelling and contractile efficiency in cardiac hypertrophy. Akki A, Seymour AM. Cardiovasc Res; 2009 Feb 15; 81(3):610-7. PubMed ID: 19028723 [Abstract] [Full Text] [Related]
5. CD36 inhibition prevents lipid accumulation and contractile dysfunction in rat cardiomyocytes. Angin Y, Steinbusch LK, Simons PJ, Greulich S, Hoebers NT, Douma K, van Zandvoort MA, Coumans WA, Wijnen W, Diamant M, Ouwens DM, Glatz JF, Luiken JJ. Biochem J; 2012 Nov 15; 448(1):43-53. PubMed ID: 22780108 [Abstract] [Full Text] [Related]
6. Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced hyperglycemia. Smith AC, Mullen KL, Junkin KA, Nickerson J, Chabowski A, Bonen A, Dyck DJ. Am J Physiol Endocrinol Metab; 2007 Jul 15; 293(1):E172-81. PubMed ID: 17374701 [Abstract] [Full Text] [Related]
7. Altered mitochondrial metabolism in the insulin-resistant heart. Makrecka-Kuka M, Liepinsh E, Murray AJ, Lemieux H, Dambrova M, Tepp K, Puurand M, Käämbre T, Han WH, de Goede P, O'Brien KA, Turan B, Tuncay E, Olgar Y, Rolo AP, Palmeira CM, Boardman NT, Wüst RCI, Larsen TS. Acta Physiol (Oxf); 2020 Mar 15; 228(3):e13430. PubMed ID: 31840389 [Abstract] [Full Text] [Related]
8. High Fat Diet Upregulates Fatty Acid Oxidation and Ketogenesis via Intervention of PPAR-γ. Sikder K, Shukla SK, Patel N, Singh H, Rafiq K. Cell Physiol Biochem; 2018 Mar 15; 48(3):1317-1331. PubMed ID: 30048968 [Abstract] [Full Text] [Related]
9. Molecular mechanism of lipid-induced cardiac insulin resistance and contractile dysfunction. Liu Y, Neumann D, Glatz JFC, Luiken JJFP. Prostaglandins Leukot Essent Fatty Acids; 2018 Sep 15; 136():131-141. PubMed ID: 27372802 [Abstract] [Full Text] [Related]
10. Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice. Aasum E, Cooper M, Severson DL, Larsen TS. Can J Physiol Pharmacol; 2005 Feb 15; 83(2):183-90. PubMed ID: 15791292 [Abstract] [Full Text] [Related]
11. Lipotoxicity in type 2 diabetic cardiomyopathy. van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P. Cardiovasc Res; 2011 Oct 01; 92(1):10-8. PubMed ID: 21803867 [Abstract] [Full Text] [Related]
12. CD36 deficiency rescues lipotoxic cardiomyopathy. Yang J, Sambandam N, Han X, Gross RW, Courtois M, Kovacs A, Febbraio M, Finck BN, Kelly DP. Circ Res; 2007 Apr 27; 100(8):1208-17. PubMed ID: 17363697 [Abstract] [Full Text] [Related]
13. Pioglitazone induces lipid accumulation in the rat heart despite concomitant reduction in plasma free fatty acid availability. Baranowski M, Blachnio-Zabielska A, Zabielski P, Gorski J. Arch Biochem Biophys; 2008 Sep 01; 477(1):86-91. PubMed ID: 18541139 [Abstract] [Full Text] [Related]
14. What are the biochemical mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db/db mice? Carley AN, Severson DL. Cardiovasc Drugs Ther; 2008 Apr 01; 22(2):83-9. PubMed ID: 18247111 [Abstract] [Full Text] [Related]
15. Metabolic profiling of hearts exposed to sevoflurane and propofol reveals distinct regulation of fatty acid and glucose oxidation: CD36 and pyruvate dehydrogenase as key regulators in anesthetic-induced fuel shift. Wang L, Ko KW, Lucchinetti E, Zhang L, Troxler H, Hersberger M, Omar MA, Posse de Chaves EI, Lopaschuk GD, Clanachan AS, Zaugg M. Anesthesiology; 2010 Sep 01; 113(3):541-51. PubMed ID: 20683255 [Abstract] [Full Text] [Related]
16. Dietary fish oil attenuates cardiac hypertrophy in lipotoxic cardiomyopathy due to systemic carnitine deficiency. Takahashi R, Okumura K, Asai T, Hirai T, Murakami H, Murakami R, Numaguchi Y, Matsui H, Ito M, Murohara T. Cardiovasc Res; 2005 Nov 01; 68(2):213-23. PubMed ID: 15963478 [Abstract] [Full Text] [Related]
17. Myocardial fatty acid metabolism and lipotoxicity in the setting of insulin resistance. Kok BP, Brindley DN. Heart Fail Clin; 2012 Oct 01; 8(4):643-61. PubMed ID: 22999246 [Abstract] [Full Text] [Related]
18. CD36 as a target to prevent cardiac lipotoxicity and insulin resistance. Glatz JF, Angin Y, Steinbusch LK, Schwenk RW, Luiken JJ. Prostaglandins Leukot Essent Fatty Acids; 2013 Jan 01; 88(1):71-7. PubMed ID: 22580174 [Abstract] [Full Text] [Related]
19. Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. Ramírez E, Klett-Mingo M, Ares-Carrasco S, Picatoste B, Ferrarini A, Rupérez FJ, Caro-Vadillo A, Barbas C, Egido J, Tuñón J, Lorenzo Ó. Cardiovasc Diabetol; 2013 Nov 21; 12():172. PubMed ID: 24261558 [Abstract] [Full Text] [Related]
20. Lipids in the heart: a source of fuel and a source of toxins. Park TS, Yamashita H, Blaner WS, Goldberg IJ. Curr Opin Lipidol; 2007 Jun 21; 18(3):277-82. PubMed ID: 17495601 [Abstract] [Full Text] [Related] Page: [Next] [New Search]